Oligomycin Complex
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
Target: ATP synthase
GI50: 270 nM
Oligomycin complex is a mixture of oligomycins A, B, and C. Oligomycin A is a selective inhibitor of ATP synthase, which can inhibit oxidative phosphorylation and all the ATP-dependent processes occurring on the coupling membrane of mitochondria, and induces apoptosis in a variety of cell types. Oligomycin B is a nonselective inhibitor of ATP synthases, which can reduce the rate of ATP depletion in myocardial ischemia.
In Vitro: In A549, H1299, H1975, H520, 786-0, H838, and U87mG cancer cell lines, 100 ng/ml Oligomycin could completely inhibit OXPHOS phosphorylation activity and stimulate various levels of glycolysis gains [1]. Besides, 5 μg/ml Oligomycin could inhibit the F0 part of H+-ATP-synthase, and strongly suppress cytochrome c release and apoptosis in Hela cells induced by TNF [2]. Furthermore, Oligomycin could inhibit mitochondrial respiration, and sensitize melanoma cells to cisplatin treatment to inhibit cell invasion [3].
In Vivo: no data available.
Clinical trial: no data available.
References:
[1] Hao W, Chang C B, Tsao C, et al. Oligomycin-induced Bioenergetic Adaptation in Cancer Cells with Heterogeneous Bioenergetic Organization[J]. Journal of Biological Chemistry, 2010, 285(17): 12647-12654.
[2] Shchepina L A, Pletjushkina O Y, Avetisyan A V, et al. Oligomycin, inhibitor of the F0 part of H+-ATP-synthase, suppresses the TNF-induced apoptosis[J]. Oncogene, 2002, 21(53): 8149.
[3] Roesch A, Vultur A, Bogeski I, et al. Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells[J]. Cancer Cell, 2013, 23(6): 811-825.
- 1. Fangfang Wang, Zhang Dan, et al. "ALCAM regulates multiple myeloma chemoresistant side population." Cell Death Dis. 2022 Feb 10;13(2):136. PMID:35145058
- 2. Beatriz Lapa, Ana Cristina Gonçalves, et al. "Acute myeloid leukemia sensitivity to metabolic inhibitors: glycolysis showed to be a better therapeutic target." Med Oncol. 2020 Jul 28;37(8):72. PMID:32725458
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 791.1(Oligomycin A) 805.1(Oligomycin B) 775.1(Oligomycin C) |
| Cas No. | 1404-19-9 |
| Formula | C45H74O11(Oligomycin A) C45H72O12(Oligomycin B) C45H74O10(Oligomycin C) |
| Solubility | ≤30 mg/ml in ethanol;20 mg/ml in DMSO;30 mg/ml in dimethyl formamide |
| SDF | Download SDF |
| Canonical SMILES | O=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H](C/C=C/C=C/[C@]([H])(CC[C@@]1([C@@H]([C@]([H])(O2)[C@H]([C@@]3(O1)C(C[C@H]([C@]([H])(O3)C[C@H](C)O)C)=O)C)C)[H])CC)C)O)O)=O)C)O)C)[C@@H]([C@H]([C@@H](/C=C/C2=O)C)O)C.O=C([C@H]([C@@H]([C@H](C([C@](C)([C@@H]([C@H |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
| Cell experiment:[1] | |
|
Cell lines |
Human cancer cell lines NCIH1299 (H1299), A549, NCI-H1975 (H1975), NCI-H1650 (H1650), NCI-H520 (H520), 786-0, NCI-H838 (H838), and U87MG |
|
Reaction Conditions |
100 ng/ml oligomycin |
|
Applications |
Oligomycin at 100 ng/ml completely inhibited oxidative phosphorylation (OXPHOS) activity in 1 h and induced various levels of glycolysis gains by 6 h. In general, cell lines with higher respiration levels showed larger gains in glycolysis flux upon oligomycin treatment. Oligomycin, as a mitochondrial ATPase inhibitor, could be used to study OXPHOS suppression-related pharmacological effects in a variety of cancer cells, including glycolysis acceleration, ATP imbalance, AMPK activation, phosphorylation of AMPK substrate acetyl-CoA carboxylase at Ser79, and cell growth inhibition. |
|
Note |
The technical data provided above is for reference only. |
|
References: 1. Hao W, Chang CP, Tsao CC, et al. Oligomycin-induced bioenergetic adaptation in cancer cells with heterogeneous bioenergetic organization. Journal of Biological Chemistry, 2010, 285(17): 12647-12654. |
|
质量控制和MSDS
- 批次:
-
纯度 ≥95.00% (Mixture of A, B, C)
- COA (Certificate Of Analysis)
- MSDS (Material Safety Data Sheet)
化学结构
相关生物数据
